PDS Biotechnology (NASDAQ:PDSB – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $21.00 target price on the stock.
A number of other research analysts also recently commented on PDSB. Cantor Fitzgerald reiterated an “overweight” rating on shares of PDS Biotechnology in a report on Thursday, May 9th. B. Riley dropped their price target on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.67.
Read Our Latest Stock Analysis on PDS Biotechnology
PDS Biotechnology Stock Down 9.3 %
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Equities analysts anticipate that PDS Biotechnology will post -1.46 EPS for the current fiscal year.
Institutional Trading of PDS Biotechnology
A number of hedge funds have recently added to or reduced their stakes in PDSB. SG Americas Securities LLC acquired a new stake in PDS Biotechnology during the 4th quarter worth approximately $52,000. Tower Research Capital LLC TRC grew its stake in shares of PDS Biotechnology by 530.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock worth $45,000 after purchasing an additional 7,612 shares during the period. Inspirion Wealth Advisors LLC lifted its stake in shares of PDS Biotechnology by 5.5% in the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock valued at $1,406,000 after purchasing an additional 18,383 shares during the period. Kathleen S. Wright Associates Inc. purchased a new stake in PDS Biotechnology during the first quarter worth about $28,000. Finally, Vanguard Group Inc. grew its position in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Read More
- Five stocks we like better than PDS Biotechnology
- Investing in Construction Stocks
- First Solar Stock: The Dawn of a New Rally in Share Prices
- 3 Healthcare Dividend Stocks to Buy
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Stock Market Upgrades: What Are They?
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.